SLU-PP-332
SLU-PP-332 is a bleeding-edge synthetic ERRγ agonist hailed as the premier "exercise mimetic." Developed by pharmacological researchers to replicate the profound metabolic adaptations of intense endurance training entirely without physical exertion. It is aggressively utilized in extreme body recomposition protocols and sarcopenia reversal to force the biology of a marathon runner onto a sedentary metabolism—driving unparalleled fat oxidation and cardiovascular mitochondrial density.
Quick Stats
Scientific Data
Mechanism of Action
SLU-PP-332 is a synthetic small molecule agonist of ERR (estrogen-related receptor) alpha and gamma nuclear receptors. It activates a transcriptional program that mimics intense aerobic exercise at the molecular level — specifically the fast-twitch to slow-twitch fiber type conversion and mitochondrial biogenesis that occur with endurance training.
ERR activation upregulates PPARGC1A (PGC-1α), the master regulator of mitochondrial biogenesis, and drives expression of slow-twitch muscle fiber genes (TNNI1, MYH7). In mouse studies, SLU-PP-332 significantly improved endurance capacity and metabolic rate, and prevented obesity on high-fat diet — mimicking the effects of exercise training without movement.
Source: PMID: 37279079
Background & History
SLU-PP-332 was developed at Saint Louis University (hence "SLU") by Thomas Burris and colleagues. Published in PNAS (2023), the compound activates ERRγ — a nuclear receptor highly expressed in metabolic tissues. The headline result: mice ran 70% longer and 45% farther than controls WITHOUT exercise training. This "exercise mimetic" effect attracted immediate interest in the longevity and performance communities. Unlike previous exercise mimetics (AICAR, GW501516), SLU-PP-332 targets a nuclear receptor rather than kinase signaling, providing a fundamentally different mechanism.
Research Use Cases
- ✓Metabolic enhancement and mitochondrial biogenesis
- ✓Research model for exercise-independent fitness adaptation
- ✓Endurance performance augmentation
- ✓Sarcopenia prevention in immobilized or elderly individuals
Dosing Protocol
| Typical Dose | 5-25 mg/day (oral) |
| Frequency | 1× daily |
| Half-Life | ~4-8 hours (estimated) |
Dosing Protocols
Research (Preclinical Only)
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 5000–25000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 3857 mcg | 11571 mcg | 19286 mcg |
| 140 lb(63 kg) | 4500 mcg | 13500 mcg | 22500 mcg |
| 160 lb(73 kg) | 5214 mcg | 15643 mcg | 26071 mcg |
| 180 lb(82 kg) | 5857 mcg | 17571 mcg | 29286 mcg |
| 200 lb(91 kg) | 6500 mcg | 19500 mcg | 32500 mcg |
| 220 lb(100 kg) | 7143 mcg | 21429 mcg | 35714 mcg |
| 250 lb(113 kg) | 8071 mcg | 24214 mcg | 40357 mcg |
💉 For exact syringe units based on your vial concentration, use the SLU-PP-332 Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Exercise Mimetic / Endurance
LowStrong preclinical data mimicking endurance exercise effects. Human data does not exist.
Safety & Considerations
ANIMAL DATA ONLY as of 2024. No human safety data exists. Extremely early-stage research compound. Not for human use outside of supervised research settings.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Pre-clinical compound — no established human interactions. Small molecule, not a peptide (oral bioavailability). Theoretical ERR family involvement in hormone-sensitive cancers — contraindicated in ER+ or hormone-sensitive malignancies. Monitor liver enzymes.
Synergies & Common Stacks
SLU-PP-332 (ERRγ → mitochondrial gene programs) + MOTS-c (AMPK → metabolic flexibility) target overlapping metabolic pathways through different mechanisms — potentially additive mitochondrial biogenesis.
SLU-PP-332 for exercise-mimetic metabolic enhancement + Epitalon for telomerase activation — a comprehensive longevity stack targeting cellular energy and cellular aging simultaneously.
Dosing Quick Reference
Frequently Asked Questions
Is SLU-PP-332 safe for humans?▼
References
- Kumar N et al. “"ERR agonist SLU-PP-332 improves exercise capacity and metabolic health".” Journal of Pharmacology and Experimental Therapeutics (2023). PMID: 37344122
Get SLU-PP-332 from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review